



Enzon to Present at 29th Annual Cowen and Company Healthcare Conference

BRIDGEWATER, N.J., Mar 16, 2009 (BUSINESS WIRE) -- Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) announced today that Jeffrey H. Buchalter, Enzon's Chairman and Chief Executive Officer, will present at the 29th Annual Cowen and Company Healthcare Conference in Boston, MA. Enzon's presentation will take place at 11:05 a.m. ET on Thursday, March 19, 2009.

About Enzon

Enzon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing, manufacturing and commercializing important medicines for patients with cancer and other life-threatening conditions. The Company has a portfolio of four marketed products, Oncaspar(R), DepoCyt(R), Abelcet(R) and Adagen(R). Enzon's drug development programs utilize several cutting-edge approaches, including our industry-leading PEGylation technology platform and the Locked Nucleic Acid (LNA) technology. Enzon's PEGylation technology was used to develop two of its products, Oncaspar and Adagen, and has created a royalty revenue stream from licensing partnerships for other products developed using the technology. The Company also engages in contract manufacturing for several pharmaceutical companies to broaden its revenue base.

Further information about Enzon and this press release can be found on the Company's web site at www.enzon.com.

SOURCE: Enzon Pharmaceuticals, Inc.

Enzon Pharmaceuticals, Inc.
Craig Tooman, 908-541-8777
EVP, Finance and
Chief Financial Officer

Copyright Business Wire 2009